

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following descriptions best characterizes the findings from the Phase II RETAIN-2 trial regarding the prognostic value of circulating tumor DNA (ctDNA) status after neoadjuvant therapy (NAT) for patients in the active surveillance group?
  - a. ctDNA status after NAT had no prognostic value
  - b. ctDNA status after NAT predicted localized disease control
  - c. ctDNA status after NAT predicted metastatic disease control
  - d. Both b and c
  
2. Which of the following statements best characterizes patient outcomes by urinary tumor DNA (utDNA) status in the Phase III NIAGARA trial evaluating neoadjuvant durvalumab and gemcitabine/cisplatin followed by radical cystectomy and adjuvant durvalumab versus neoadjuvant gemcitabine/cisplatin followed by radical cystectomy alone for patients with muscle-invasive bladder cancer (MIBC)?
  - a. utDNA status was not prognostic of survival outcomes
  - b. Clearance of utDNA was higher in the durvalumab arm before radical cystectomy
  - c. Clearance of utDNA was associated with improved event-free survival outcomes
  - d. Both b and c
  
3. Which of the following statements best describes the survival outcomes for patients with detectable ctDNA who received atezolizumab as part of the Phase III IMvigor011 study?
  - a. A nonsignificant improvement in both disease-free survival (DFS) and overall survival (OS)
  - b. An improvement in DFS
  - c. An improvement in OS
  - d. Both b and c
  
4. What was the approximate 2-year DFS rate for patients enrolled in the Phase III IMvigor011 study whose ctDNA was persistently undetectable?
  - a. 68%
  - b. 78%
  - c. 88%
  - d. 98%
  
5. The Phase III POTOMAC trial evaluating durvalumab and bacillus Calmette-Guérin (BCG) versus BCG alone for patients with BCG-naïve high-risk non-muscle-invasive bladder cancer reported which of the following efficacy findings?
  - a. Inferior DFS with durvalumab and BCG
  - b. A nonsignificant trend toward improvement in DFS with durvalumab and BCG
  - c. A statistically significant improvement in DFS with durvalumab and BCG
  - d. No efficacy findings have been reported yet